Organization | St. Baldrick's Foundation

St. Baldrick's Foundation Report issue

Foundation Phase 1 Phase 2

Founded: Monrovia CA United States (1999)

Organization Overview

First Clinical Trial

2013

NCT01772953

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

St. Baldrick's Foundation

Active Ingredients

Drugs in Phase 2 Trials (9)

allogeneic stem cells (1 trial)

brentuximab vedotin (adcetris) (1 trial)

cd33 car-t cells (1 trial)

clofarabine (clolar) (1 trial)

gemcitabine (gemzar) (1 trial)

metformin (glucophage) (1 trial)

moxetumomab pasudotox (Lumoxiti) (1 trial)

treosulfan (1 trial)

vitamin c (2 trials)

Drugs in Phase 1 Trials (2)

nivolumab (opdivo) (1 trial)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Histiocytosis (Phase 2)

Histiocytosis, Langerhans-Cell (Phase 2)

Hodgkin Disease (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lymphoma (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasm, Residual (Phase 2)

Osteosarcoma (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Sarcoma (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 9
# of Trial APIs: 11